Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates.

Bibbiani F, Costantini LC, Patel R, Chase TN.

Exp Neurol. 2005 Mar;192(1):73-8.

PMID:
15698620
2.

Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).

Maratos EC, Jackson MJ, Pearce RK, Cannizzaro C, Jenner P.

Exp Neurol. 2003 Jan;179(1):90-102.

PMID:
12504871
3.

Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys.

Samadi P, Grégoire L, Hadj Tahar A, Di Paolo T, Rouillard C, Bédard PJ.

Neuropharmacology. 2005 Aug;49(2):165-73. Epub 2005 Mar 29.

PMID:
15996565
4.
5.

Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models.

Oh JD, Bibbiani F, Chase TN.

Exp Neurol. 2002 Oct;177(2):557-64.

PMID:
12429201
6.

Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys.

Hadj Tahar A, Ekesbo A, Grégoire L, Bangassoro E, Svensson KA, Tedroff J, Bédard PJ.

Eur J Pharmacol. 2001 Feb 2;412(3):247-54.

PMID:
11166288
8.

Translating A2A antagonist KW6002 from animal models to parkinsonian patients.

Chase TN, Bibbiani F, Bara-Jimenez W, Dimitrova T, Oh-Lee JD.

Neurology. 2003 Dec 9;61(11 Suppl 6):S107-11. Review.

PMID:
14663022
9.

Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results.

Stocchi F, Vacca L, De Pandis MF, Barbato L, Valente M, Ruggieri S.

Neurol Sci. 2001 Feb;22(1):93-4.

PMID:
11487217
11.

Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.

Deleu D, Hanssens Y, Northway MG.

Drugs Aging. 2004;21(11):687-709. Review.

PMID:
15323576
12.
13.

L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys.

Huot P, Lévesque M, Morissette M, Calon F, Dridi M, Di Paolo T, Parent A.

J Chem Neuroanat. 2008 Jan;35(1):77-84. Epub 2007 Jul 17.

PMID:
17706922
14.

A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease.

Bibbiani F, Oh JD, Petzer JP, Castagnoli N Jr, Chen JF, Schwarzschild MA, Chase TN.

Exp Neurol. 2003 Nov;184(1):285-94.

PMID:
14637099
15.

Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.

Katzenschlager R, Hughes A, Evans A, Manson AJ, Hoffman M, Swinn L, Watt H, Bhatia K, Quinn N, Lees AJ.

Mov Disord. 2005 Feb;20(2):151-7.

PMID:
15390035
16.

Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.

Blanchet PJ, Konitsiotis S, Chase TN.

Mov Disord. 1998 Sep;13(5):798-802.

PMID:
9756148
18.
19.

Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.

Grégoire L, Samadi P, Graham J, Bédard PJ, Bartoszyk GD, Di Paolo T.

Parkinsonism Relat Disord. 2009 Jul;15(6):445-52. doi: 10.1016/j.parkreldis.2008.11.001. Epub 2009 Feb 3.

PMID:
19196540
20.

[Apomorphine in the treatment of Parkinson's Disease].

Dressler D.

Nervenarzt. 2005 Jun;76(6):681-9. Review. German.

PMID:
15592807

Supplemental Content

Support Center